MedTrace Logo

Genicular Nerve Block Added to Femoral Nerve Block for Analgesia After Total Knee Arthroplasty

NCT07478783 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-03-25

No results posted yet for this study

Summary

Total knee arthroplasty (TKA) is a common orthopedic procedure in which effective postoperative pain management is important for early mobilization and rehabilitation. Various regional anesthesia techniques are used as part of multimodal analgesia protocols to improve postoperative pain control. Genicular nerve block has recently been introduced as a potential motor-sparing technique that may enhance postoperative analgesia when used alone or in combination with other regional blocks.

The aim of this randomized controlled study is to evaluate whether the addition of ultrasound-guided genicular nerve block to femoral nerve block improves early postoperative analgesia in patients undergoing primary unilateral total knee arthroplasty under combined spinal-epidural anesthesia.

A total of 80 patients aged 18-80 years scheduled for elective primary unilateral TKA will be included and randomly assigned to two groups using sealed envelopes. One group will receive femoral nerve block alone (Group F), while the other group will receive femoral nerve block combined with genicular nerve block (Group FG). Postoperative pain scores using the visual analog scale (VAS), epidural patient-controlled analgesia consumption during the first 24 hours, and the time to additional analgesic requirement will be recorded and compared between the groups.

Conditions

  • Total Knee Anthroplasty

Interventions

PROCEDURE

Ultrasound-guided Femoral Nerve Block

Administration of 20 ml of 0.25% bupivacaine to the femoral nerve under ultrasound guidance. This procedure was performed on patients in both Group F and Group FG

PROCEDURE

ltrasound-guided Genicular Nerve Block

Administration of 5 ml of 0.25% bupivacaine to each of the four genicular nerve branches (superomedial, superolateral, inferomedial, and inferolateral) under ultrasound guidance. This procedure was performed only on patients in Group FG

Sponsors & Collaborators

  • Ankara City Hospital Bilkent

    lead OTHER

Principal Investigators

  • Semih Baskan, Proffesor · Ankara City Hospital Bilkent

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2021-11-01
Completion
2022-02-28

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07478783 on ClinicalTrials.gov